Rgenta Therapeutics Inc.

The spirit of science and teamwork shined at the Rgenta Olympics!? ? This past week, the Rgenta team came together for a unique "Olympics" experience filled with science-themed games, friendly competition, and activities that showcased our skills and passions.?? ? A huge thank you to everyone who participated and helped organize this memorable event — we’re already excited for next year!?

The spirit of science and teamwork shined at the Rgenta Olympics!? ? This past week, the Rgenta team came together for a unique "Olympics" experience filled with science-themed games, friendly competition, and activities that showcased our skills and passions.?? ? A huge thank you to everyone who participated and helped organize this memorable event — we’re already excited for next year!?

Rgenta Co-founder, President and CSO Travis Wager, Ph.D., will discuss Rgenta’s approach to developing RNA-targeting small molecules that reduce levels of?PMS1 for the potential treatment of Huntington’s Disease in a presentation at the 2024 Huntington Study Group (HSG) Annual Meeting today at 4:30 pm ET.?? ? Learn more about the event here: https://lnkd.in/gE_YS9pc? ? #HSG2024?

Rgenta Senior Scientist, Ibrahim Kays, Ph.D., will present a poster highlighting Rgenta’s approach to oral, small-molecule RNA-targeting medicines for the potential treatment of repeat expansion disorders at the 2024 Huntington Study Group (HSG) Annual Meeting on Thursday, November 7, 2024 at 5:30 p.m. ET. Learn more about the event here: https://lnkd.in/gE_YS9pc #HSG2024

We are pleased to share that a poster highlighting preclinical data demonstrating the potential of RGT-61159, our oral small molecule MYB inhibitor, to treat acute myeloid leukemia (AML) has been accepted for presentation at the 66th American Society of Hematology (ASH) Annual Meeting taking place December 7-10, 2024, in San Diego, CA.?? ? Learn more here: https://lnkd.in/gKHj2Jqh

We’re proud to have participated in the Light the Night Walk hosted by the The Leukemia & Lymphoma Society (LLS)!?? ? #TeamRgenta united to raise essential funds in the fight against blood cancers, supporting groundbreaking research and targeted therapies through employee contributions and a company match.?? ? It was an inspiring evening filled with hope, unity, and dedication to making a difference for the 1.6 million people living with or in remission from blood cancer.?? ? A big thank you to everyone who supported us in this meaningful cause!?? ? #LightTheNight #BloodCancerAwareness?

We’re proud to participate in the Light the Night Walk sponsored by The Leukemia & Lymphoma Society (LLS) to shine a light of hope for the 1.6 million people in the U.S. living with or in remission from blood cancers.?? ? Together, we can help LLS advance life-changing targeted therapies that bring hope to patients and their families. Join us in supporting this vital cause and walking towards a future free from cancer. #LightTheNight #BloodCancerAwareness? ? Take action and explore how to get involved: https://lnkd.in/gw-J38ra?

We are excited to announce that we have dosed the first cohort of patients in our first-in-human Phase 1a/b clinical trial to evaluate oral small molecule drug candidate, RGT-61159 in patients with adenoid cystic carcinoma (ACC) or colorectal cancer (CRC).?? ? RGT-61159 is designed to selectively target MYB RNA and inhibit oncogenic MYB protein production whose aberrant expression has been demonstrated in multiple forms of human cancer including ACC, CRC, acute myeloid leukemias (AML), T-cell acute lymphoblastic leukemias (T-ALL), small cell lung cancer (SCLC) and breast cancer.??? ? Learn more about RGT-61159 here: https://lnkd.in/gYBpyvrm

Executive Director and Head of Medicinal Chemistry, Chris Yates will discuss Rgenta’s approach to developing oral, small-molecule RNA-targeting medicines in a presentation at the 22nd Annual Discovery on Target Conference. The presentation will take place today at 5:05 p.m. ET. Be sure to tune in if you’re attending this week’s event. Learn more here: https://bit.ly/3TQTQE2

Rgenta Co-founder, President and CSO Travis Wager, Ph.D., will join other leading industry experts to explore the latest advances in basic, translational and clinical Huntington’s Disease (HD) research at the European Huntington's Disease Network (EHDN) and Enroll-HD 2024 meeting. Don’t miss Dr. Wager’s presentation on Rgenta’s approach to developing RNA-targeting small molecules that reduce levels of?PMS1 for the potential treatment of Huntington’s Disease if you’re attending the meeting. Learn more about this year’s event here: https://ehdn.org/ehdn2024/ #EHDN2024 #HuntingtonsDisease